Earnings Call Intelligence Subscribe
Home › Call Sheets › MRK › Q3'25
Call sheet · Q3'25

Merck (MRK)

Q3'25 earnings call · held 2025-10-30 · compared with the Q2'25 call · management-credibility review
11/12
Disclosure score
6 low flags
Financial quality
Bottom line
The sleeper story is WINREVAIR's real demand trajectory being masked by distributor timing - the $40M Q3 headwind that 'fully reversed in October' suggests underlying momentum is much stronger than the $360M reported. While everyone focuses on KEYTRUDA's 8% growth, the real story is earlier-stage mix now exceeds 25% and drives over half of growth - this isn't decline, it's portfolio transformation accelerating. The binding constraint is execution bandwidth with 80 Phase III trials and multiple launches requiring massive 2026 investment increases. Rob's quote captures it: 'We will be growing our spend over time...reallocating from slower growth areas to fully fund into fast-growing areas.' My view changes if Q4 WINREVAIR doesn't show the promised distributor recovery or if 2026 expense guidance exceeds 15% growth.

The 30-second version

  • WINREVAIR distributor timing games mask real demand acceleration
  • KEYTRUDA earlier-stage now exceeds 25% of sales, driving over half of growth
  • China GARDASIL inventory problem extending through 2026

What changed this quarter

MetricQ2'25Q3'25Change
Total Revenue$15.8B (-2%)$17.3B (+4%)Acceleration to growth despite GARDASIL China drag
KEYTRUDA Sales$8.0B (+9%)$8.1B (+8%)Slight deceleration but ahead of QLEX launch
WINREVAIR Sales$336M (strong momentum)$360M (with $40M timing headwind)Real demand stronger than reported with October recovery
GARDASIL Sales$1.1B (-55%)$1.7B (-25%)Less bad but still China-impacted, Japan headwinds persist
CAPVAXIVE Sales$129M (strong launch)$244M (+89% sequential)Seasonal inventory build plus retail demand surge
WELIREG Sales$162M (+29%)$196M (+41%)Accelerating growth ahead of Phase III readouts
Animal Health Sales11% growth7% growthDeceleration but still solid double-digit livestock growth
Operating Expenses$6.6B (4% growth ex-charges)$6.6B (flat ex-charges)Expense discipline while investing in 80+ Phase III trials
EPS Non-GAAP$2.13$2.5821% jump driven by product mix and expense control
Gross Margin82.2% (+1.3 pts)81.9% (+1.4 pts)Stable improvement from favorable product mix

Accountability tracked

8 new promises made4 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full MRK Q3'25 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.